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542Variants at HLA-A, HLA-C, and HLA-DQB1
Confer Risk of Psoriasis Vulgaris in Japanese
Jun Hirata1,2,3, Tomomitsu Hirota4, Takeshi Ozeki5, Masahiro Kanai1,6, Takeaki Sudo7,
Toshihiro Tanaka3,8, Nobuyuki Hizawa9, Hidemi Nakagawa10, Shinichi Sato11, Taisei Mushiroda5,
Hidehisa Saeki12, Mayumi Tamari4,13 and Yukinori Okada1,6,14Psoriasis vulgaris (PsV) is an autoimmune disease of skin and joints with heterogeneity in epidemiologic and
genetic landscapes of global populations. We conducted an initial genome-wide association study and a
replication study of PsV in the Japanese population (606 PsV cases and 2,052 controls). We identified significant
associations of the single nucleotide polymorphisms with PsV risk at TNFAIP3-interacting protein 1and the
major histocompatibility complex region (P ¼ 3.7  1010 and 6.6  1015, respectively). By updating the HLA
imputation reference panel of Japanese (n ¼ 908) to expand HLA gene coverage, we fine-mapped the HLA
variants associated with PsV risk. Although we confirmed the PsV risk of HLA-C*06:02 (odds ratio ¼ 6.36,
P ¼ 0.0015), its impact was relatively small compared with those in other populations due to rare allele
frequency in Japanese (0.4% in controls). Alternatively, HLA-A*02:07, which corresponds to the cysteine residue
at HLA-A amino acid position 99 (HLA-A Cys99), demonstrated the most significant association with PsV (odds
ratio ¼ 4.61, P ¼ 1.2  10e10). In addition to HLA-A*02:07 and HLA-C*06:02, stepwise conditional analysis
identified an independent PsV risk of HLA-DQb1 Asp57 (odds ratio ¼ 2.19, P ¼ 1.9  10e6). Our PsV genome-
wide association study in Japanese highlighted the genetic architecture of PsV, including the identification
of HLA risk variants.
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Psoriasis vulgaris (PsV) is a chronic immune-mediated
disease of skin and joints characterized by inflamma-
tion, epidermal hyperplasia, and vascular remodeling
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an open access artenvironmental and genetic factors contribute substantially to
the development of PsV (Nestle et al., 2009). To date, large-
scale genome-wide association studies (GWAS) have identi-
fied more than 60 genetic loci associated with PsV risk (e.g.,
IL23R, REL, IL12B, TNFAIP3, and ERAP1). The functional
annotation of these loci implicated biological pathways
related to disease biology of PsV including IL signaling and
an NF-kB pathway (Tang et al., 2014; Tsoi et al., 2015, 2017;
Sheng et al., 2014; Yin et al., 2015; Zuo et al., 2015). In
addition to the common single nucleotide polymorphisms
(SNPs) identified by GWAS, rare mutations associated with
familial forms of PsV were detected by sequence analyses
(Hayashi et al., 2014; Jordan et al., 2012).
As observed in other immune-related diseases, the major
histocompatibility complex (MHC) region at 6p21 confers
the strongest genetic risk of PsV. PsV risk within MHC
was originally mapped to a critical region at MHC
class I, termed PSORS1 (Tiilikainen et al., 1980); then,
HLA-C*06:02 was identified as the causal allele that ex-
plains the risk of PSORS1 (Nair et al., 2006). The strong PsV
risk of HLA-C*06:02 allele has been validated in worldwide
populations including Europeans (Lenz et al., 2015; Okada
et al., 2014a), South Asians (Chandra et al., 2016), and East
Asians (Mabuchi et al., 2014; Zhou et al., 2016), with an
odds ratio (OR) of as high as 3.0e10.0. However, the
genetic landscape of PsV within MHC has yet to be eluci-
dated. HLA fine-mapping analysis using the HLA imputation
method successfully identified multiple HLA variants with
PsV risk independently from HLA-C*06:02 (Okada et al.,
2014a). For example, HLA imputation analysis in Euro-
peans reported that amino acid polymorphisms in HLA-A,
HLA-B, and HLA-DQA1 confer independent PsV risk. Thus,s. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology. This is
icle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. A Manhattan plot of the genome-wide association study (GWAS)
of psoriasis vulgaris in the Japanese population. A Manhattan plot showing
elog10(P) of the genome-wide single nucleotide polymorphisms (SNPs) in the
GWAS of psoriasis vulgaris in the Japanese population (after SNP imputation).
The black horizontal line represents the genome-wide significance threshold
of P ¼ 5.0  10e8. The genetic loci that satisfied the genome-wide
significance threshold in the combined analysis of the GWAS and the
replication study are labeled. MHC, major histocompatibility complex.
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ulations are warranted.
Epidemiologic studies reported that the prevalence and
incidence of PsV shows ethnic and geographic variations
(Chandran et al., 2010; Parisi et al., 2013). Although a rela-
tively high prevalence is observed in European countries and
in the USA (0.5e6.5%), the prevalence in East Asian coun-
tries is low (0.2e0.3%) (Chandran et al., 2010; Parisi et al.,
2013). Because of the strong PsV risk of HLA-C*06:02,
global heterogeneity of PsV is considered to be partially
explained by the allele frequency spectra of HLA-C*06:02.
There appears to be a lower HLA-C*06:02 prevalence, and
consequently a lower rate of PsV, within the populations
whose ancestors migrated to the orient (Chandran et al.,
2010, 2016). From this perspective, the Japanese popula-
tion has unique characteristics. PsV prevalence in Japan is
one of the lowest compared with worldwide populations
(0.1e0.3%) (Kubota et al., 2015; Naito et al., 2016;
Takahashi et al., 2009), and the frequency of HLA-C*06:02
is almost rare within the Japanese population (<0.5%)
(Mabuchi et al., 2014). This may suggest that the Japanese
patients with PsV have a higher proportion of HLA-C*06:02-
negative individuals; thus, genetic studies investigating the
Japanese population could contribute to unveiling novel
genetic architecture associated with PsV. However, a
genome-wide assessment of PsV risk has not been conducted
in the Japanese population to date.
In this study, we conducted an initial GWAS of PsV and a
replication study within the Japanese population (in total 606
PsV cases and 2,052 controls). We then applied the HLA
imputation method to the GWAS data by updating the HLA
reference panel of the Japanese population to comprehen-
sively fine-map the risk of the HLA variants (n ¼ 908).
RESULTS
PsV GWAS in the Japanese population
In the PsV GWAS, 282 PsV cases and 426 controls were
enrolled from the Japanese population. Genotyping of the
genome-wide SNPs was performed using Illumina Human-
CoreExome BeadChip (Illumina, San Diego, CA). We applied
stringent quality control (QC) filters, and obtained 255,632
autosomal SNPs. To extend the coverage of the SNPs, we
conducted whole-genome SNP genotype imputation using a
multiethnic reference panel of the 1000 Genomes Project
(phase 3v5; n ¼ 2,504). After SNP imputation, 6,369,185
autosomal SNPs that satisfied the criteria of minor allele
frequency (MAF)  0.5% and imputation score (Rsq by
minimac2)  0.7 were obtained. Associations of the SNPs
with PsV risk were evaluated using a logistic regression model.
Quantile-quantile plots of the genome-wide P-values
indicated no remarkable inflation of test statistics both before
and after SNP imputation (lGC ¼ 1.007 and 1.003, respec-
tively; Supplementary Figure S1 online), which suggested
that no substantial population stratification exists in the
studied subjects. As observed in the previous PsV GWAS in
other populations (Sheng et al., 2014; Tang et al., 2014;
Tsoi et al., 2015, 2017; Yin et al., 2015; Zuo et al., 2015),
the most significant association signal that satisfied the
genome-wide significance threshold of P < 5.0  10e8
(Kanai et al., 2016) was observed within the MHC region(P ¼ 1.0  10e8 at rs3132506 and P ¼ 2.8  10e9 at
rs378352 before and after SNP imputation, respectively;
Figure 1 and Supplementary Figure S2 online).
Replication study
To further explore the PsV risk SNPs in the Japanese popu-
lation, we conducted a replication study that enrolled an
independent PsV case-control cohort of Japanese individuals
(320 PsV cases and 1,622 controls). We selected 22 loci that
satisfied P < 5.0  10e4 in the GWAS, and performed
genotyping of the lead SNP of each loci (Supplementary
Table S1 online). Of these, SNPs in two loci (rs2233278 at
TNFAIP3-interacting protein 1 and rs9394026 at the MHC
region) showed nominal association signals with the same
directional effects that were observed in the GWAS
(P ¼ 7.0  10e6 and 9.6  10e8, respectively). TNFAIP3-
interacting protein 1 is a known PsV risk locus implicated
in regulation of an NF-kB pathway and microRNA (Okada
et al., 2016a; Olarerin-George et al., 2013), and an associ-
ation of rs2233278 with PsV was reported in the Japanese
population (Tamari et al., 2014). After the meta-analysis
combining the GWAS and the replication study, these two
SNPs demonstrated associations that satisfied the genome-
wide significance threshold (OR ¼ 1.96, 95% confidence
interval [95% CI] ¼ 1.59e2.41, P ¼ 3.7  10e10 for
rs2233278 at TNFAIP3-interacting protein 1, and OR ¼ 1.86,
95% CI ¼ 1.59e2.18, P ¼ 6.6  10e15 for rs378352 at the
MHC region; Table 1).
Update of the HLA imputation reference panel of Japanese
To fine-map the risk of HLA variants of PsV in the Japanese
population, we applied the HLA imputation method to the
PsV GWAS data using the previously constructed Japanese
population-specific reference panel (n ¼ 908) (Okada et al.,
2015, 2016b; Shiraishi et al., 2016). To expand the coverage
of the HLA genes for imputation, we newly genotyped the
HLA-DQA1 alleles of the subjects in the reference panel. The
updated reference panel included three class I HLA genes
(HLA-A, HLA-B, and HLA-C) and five class II HLA genes
(HLA-DRB1, HLA-DQA1, HLA-DQB1, HLA-DPA1, and
HLA-DPB1). Empirical evaluation of imputation accuracy
based on a cross-validation approach demonstrated highwww.jidonline.org 543
Table 1. SNPs with genome-wide significant associations with psoriasis vulgaris risk in Japanese
rsID Chr
Position
(hg19)
Allele
1/2 Gene Study stage
No. of subjects Allele 1 freq. PsV association
PsV Control PsV Control OR (95%CI) P
rs2233278 5 150,467,189 C/G TNIP1 GWAS 282 426 0.138 0.070 2.62 (1.75e3.92) 3.0  10e6
Replication 313 1,620 0.157 0.095 1.76 (1.37e2.25) 7.0  10e6
Meta-analysis 595 2,046 0.148 0.090 1.96 (1.59e2.41) 3.7  10e10
rs9394026 6 30,982,544 G/A MHC region GWAS 282 426 0.303 0.168 2.25 (1.72e2.95) 2.8  10e9
Replication 313 1,620 0.302 0.204 1.69 (1.39e2.04) 9.6  10e8
Meta-analysis 595 2,046 0.302 0.197 1.86 (1.59e2.18) 6.6  10e15
Abbreviations: CI, confidence interval; GWAS, genome-wide association study; MHC, major histocompatibility complex; OR, odds ratio; PsV, psoriasis
vulgaris; SNP, single nucleotide polymorphism.
Figure 2. Regional associations of the variants in the major
histocompatibility complex (MHC) region with psoriasis vulgaris risk.
Regional associations of the variants in the MHC region with psoriasis
vulgaris risk in the Japanese population estimated based on the HLA
imputation analysis. (a) Nominal regional associations. (bed) Stepwise
analysis results conditioned on HLA-C*06:02, HLA-A, and HLA-DQB1. Each
diamond represents the elog10(P) of the variants, including the single
nucleotide polymorphism, two-digit and four-digit HLA alleles, and amino
acid polymorphisms of HLA genes. The dotted horizontal line represents the
region-wide significance threshold of P ¼ 6.0  10e6. The most strongly
associated variant in each panel is labeled.
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544concordance rates between imputed and genotyped HLA
alleles (on average 98.4% and 95.9% for the two-digit and
four-digit alleles, respectively; Supplementary Table S2
online).
HLA imputation of the PsV GWAS data
We imputed HLA variants of the PsV GWAS data using the
updated reference panel of Japanese and SNP2HLA (Jia et al.,
2013; Okada et al., 2014b; Raychaudhuri et al., 2012), one
of the most accurate HLA imputation programs (Karnes et al.,
2017). After the application of postimputation QC filters
(MAF  0.1% and 0.5% for the HLA variants and the SNPs,
respectively, and an imputation score Rsq  0.5), we
obtained genotypes of 71 two-digit HLA alleles, 117 four-
digit HLA alleles, 958 amino acid residues, and 6,477 SNPs
in the MHC region (from 29 to 34 Mbp at chromosome 6,
NCBI build 37). We assessed the PsV risk of each imputed
variant with a binary test (n ¼ 7,623) and each amino acid
position of the HLA genes by an omnibus test (n ¼ 688).
We set the regional significance threshold according to
Bonferroni’s correction based on the number of tests
(a ¼ 0.05; P ¼ 0.05/8,311 ¼ 6.0  10e6).
Interestingly, the most significant PsV association within
MHC was observed not at HLA-C*06:02, but at
HLA-A*02:07, which corresponds to a cysteine residue of
HLA-A amino acid position 99 in Japanese (OR ¼ 4.61, 95%
CI ¼ 2.79e7.61, P ¼ 1.2  10e10; Figure 2a) that satisfied the
region-wide significance threshold. Although we observed an
association of HLA-C*06:02 (OR ¼ 6.36, 95% CI ¼
1.70e23.8, P ¼ 0.0015), its impact on PsV susceptibility was
less apparent compared with those observed in other pop-
ulations due to low allele frequency in the Japanese popu-
lation (2.3% in PsV cases and 0.4% in controls). We note that
HLA-C*12:03, another HLA-C risk allele of PsV in Europeans,
was also rare in Japanese (0.1% in controls). Although HLA-
C*12:03 showed the same directional effect as observed in
Europeans, its association was not significant in Japanese
(OR ¼ 7.41, 95% CI ¼ 0.47e117.6, P ¼ 0.13). When
conditioned on HLA-C*06:02, HLA-A*02:07 (and HLA-A
Cys99) still demonstrated significant PsV risk (OR ¼ 4.61,
95% CI ¼ 2.79e7.63, P ¼ 1.5  10e10; Figure 2b). No other
HLA-A variant showed a significant association when
conditioned on HLA-C*06:02 and HLA-A*02:07 (P > 0.077),
which suggested that the PsV risk of HLA-A in Japanese could
be explained by that of HLA-A*02:07 (and HLA-A Cys99).Journal of Investigative Dermatology (2018), Volume 138Alternatively, when we conditioned on HLA-A first, we also
observed an association of HLA-C*06:02 (P ¼ 0.0018).
To further explore additional HLA variants that confer
independent PsV risk, we conducted a conditional analysis
on HLA-C*06:02 and HLA-A. We observed a significant
association in the MHC class II region, which was highlighted
at an aspartic acid residue of HLA-DQb1 amino acid position
Table 2. Associations of the HLA variants for psoriasis vulgaris risk in Japanese
Variant
Frequency
OR (95% CI) P Explained risk in the populationPsV Control
HLA-A*02:071 0.112 0.028 4.19 (2.52e6.97) 3.4  10e8 0.013
HLA-C*06:02 0.023 0.0040 10.27 (2.59e40.73) 9.2  10e4 0.0054
HLA-DQb1 57Asp 0.825 0.729 1.98 (1.47e2.67) 7.4  10e6 0.018
Abbreviations: CI, confidence interval; OR, odds ratio; PsV, psoriasis vulgaris.
1Equivalent to HLA-A Cys99 in the Japanese population.
Figure 3. Psoriasis vulgaris risk amino acid positions of HLA genes in three-
dimensional ribbon models. HLA amino acid positions with psoriasis vulgaris
risk in HLA-A and HLA-DQ molecules are indicated in three-dimensional
ribbon models. The protein structures of HLA-A and HLA-DQ are based on
Protein Data Bank entries 1x7q and 1jk8, respectively, and prepared using
UCSF Chimera (version 1.7). Residues at amino acid positions with PsV risk in
Japanese (this study) and Europeans (Okada et al., 2014a) are highlighted in
yellow and blue, respectively.
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HLA Variants Confer Risk of Psoriasis Vulgaris57 (OR ¼ 2.19, 95% CI ¼ 1.57e3.07, P ¼ 1.9  10e6;
Figure 2c). No other variants in the MHC region satisfied the
region-wide significance threshold when conditioned on
HLA-C*06:02, HLA-A, and HLA-DQb1 Asp57 (or HLA-
DQB1; Figure 2d), whereas suggestive associations of other
HLA genes such as HLA-B (the smallest P ¼ 5.8  10e4 and
P ¼ 7.1  10e4 at HLA-B*15:18 and HLA-B Cys67, respec-
tively) or HLA-DRB1 (the smallest P ¼ 2.5  10e4 at HLA-
DRb1 amino acid position 149) were observed. Of these,
HLA-B Cys67 was reported as a PsV risk variant in Europeans
(Okada et al., 2014a).
In summary, imputation-based HLA fine-mapping analysis
demonstrated that the PsV risk of MHC could be explained by
combinations of the multiple class I and class II HLA genes in
the Japanese population (HLA-C*06:02, HLA-A*02:07 [i.e.,
HLA-A Cys99], and HLA-DQb1 Asp57). A multivariate full
regression model including these risk variants (Table 2)
explained 3.6% of the overall PsV risk in the population
under the assumption of 0.2% of disease prevalence (Kubota
et al., 2015; Naito et al., 2016; Takahashi et al., 2009). As
expected, the impact of HLA-C*06:02 (0.54%) was relatively
smaller than those of HLA-A*02:07 and HLA-DQb1 Asp57
(1.3% and 1.8%, respectively). We did not observe nonad-
ditive effects of the risk variants (Pnonadditive > 0.43). Although
localization of HLA-C*06:02 to specific amino acid positions
of HLA-C is known to be difficult (Clop et al., 2013; van den
Bogaard et al., 2016; Vince et al., 2016), PsV risk amino acid
polymorphisms of HLA-A Cys99 and HLA-DQb1 Asp57 were
located at functional pockets of HLA-A and HLA-DQ mole-
cules (Figure 3), suggesting their biological impacts.
DISCUSSION
In this study, we conducted an initial GWAS of PsV in the
Japanese population. Combined analysis of the GWAS and
the replication study confirmed PsV risk at TNFAIP3-
interacting protein 1 and the MHC region. We further per-
formed HLA risk fine-mapping analysis by updating the HLA
imputation reference panel, and found that combinations
of the multiple HLA variants at class I and class II HLA
genes (HLA-C*06:02, HLA-A*02:07 [i.e., HLA-A Cys99], and
HLA-DQb1 Asp57) explained PsV risk within the MHC
region in Japanese.
Although HLA-C*06:02 has shown the strongest associa-
tion with PsV in other populations (Lenz et al., 2015; Okada
et al., 2014a; Zhou et al., 2016), its impact in the Japanese
population was relatively small due to rare allele frequency
(<0.5%). Our study has identified for the first time a popu-
lation in which HLA-C*06:02 is not the strongest genetic riskfactor for psoriasis. We note that our large-scale imputation
reference panel achieved high imputation quality of HLA-
C*06:02 despite its low frequency (Rsq ¼ 0.91). A leave-
one-out cross-validation empirically demonstrated 100% of
sensitivity in imputation of HLA-C*06:02. These results might
reject the possibility that the impact of HLA-C*06:02 was
underestimated due to inaccurate imputation. Previous
studies reported that the PsV risk of the HLA-C variants such
as HLA-C*06:02 and HLA-C*12:02 is associated with age of
onset (Bowes et al., 2017; Mabuchi et al., 2014). Further
stratified analysis based on age of onset would be warranted
to comprehensively elucidate genetic landscape of PsV in the
Japanese population.
Alternatively, HLA-A*02:07 demonstrated the most signif-
icant association with PsV in Japanese. Associations of
HLA-A*02 with PsV and psoriatic arthritis were previously
reported in Japanese (Muto et al., 1995; Nakagawa et al.,
1991), which was subsequently found to be driven by an
association of HLA-A*02:07 (Muto et al., 1996). Previous
studies in the Chinese population suggested the PsV risk of
HLA-A*02:07, but this result was met with controversial
discussions (Yin et al., 2015; Zhou et al., 2016). Our study
robustly confirmed the PsV risk of HLA-A*02:07 that satisfied
the genome-wide significance threshold. Although HLA-
A*02:07 has a variety of allele frequency spectra in world-
wide populations, its frequency in Japanese (¼0.028) iswww.jidonline.org 545
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546relatively higher than those in other populations (e.g., 0.020
in East Asians and 0.0028 in Europeans) (Okada et al., 2015).
HLA-A*02:07 corresponds to HLA-A Cys99 in the Japanese
population. A previous MHC fine-mapping study in Euro-
peans reported the PsV risk of HLA-A amino acid position 95,
which is closely located to the risk amino acid position 99
identified in the Japanese population (Figure 3). This may
suggest that HLA-A amino acid positions around 95e99 have
biological impacts on PsV pathogenicity.
We further identified the PsV risk amino acid poly-
morphism of HLA-DQb1 (Asp57). A previous study in
Europeans pointed PsV risk amino acid polymorphism of
HLA-DQa1, proposing the hypothesis that HLA-DQ mole-
cules might also have crucial roles in PsV disease biology
(Okada et al., 2014a). The PsV risk of HLA alleles that carry
HLA-DQb1 Asp57 has been reported in previous studies in
Japanese (Nakagawa et al., 1990; Saeki et al., 1998). We also
note that HLA-DQb1 Asp57 is known to be associated with
type 1 diabetes mellitus in European (Hu et al., 2015). These
results should implicate that the amino acid position 57 has
critical functional roles in diseases biology.
In conclusion, our initial PsV GWAS in the Japanese pop-
ulation highlighted genetic architecture of PsV including
identification of novel HLA risk variants, which was different
from previous findings in other populations. Our study should
motivate further accumulation of genetic studies from a
variety of populations to further elucidate the disease biology
of PsV.
MATERIAL AND METHODS
Subjects
We enrolled 606 PsV cases and 2,052 controls for the GWAS and
the replication study. Genomic DNA from the PsV cases and the
controls enrolled in the GWAS (n ¼ 282 [mean  standard deviation
age ¼ 51.7  15.2, female ratio ¼ 0.20] and 426 [mean  standard
deviation age ¼ 38.2  0.4, female ratio ¼ 0.45], respectively) were
obtained from Epstein-Barr virus transformed B-lymphoblast cell
lines of unrelated Japanese individuals established by the Japan
Biological Informatics Consortium. The PsV cases in the replication
study (n ¼ 324 [mean  standard deviation age ¼ 53.8  15.3,
female ratio ¼ 0.26]) were collected from three medical institutes in
Japan (the Jikei University School of Medicine, Nippon Medical
School, and the University of Tokyo) (Tamari et al., 2014). The
controls in the replication study (n ¼ 1,626 [mean  standard
deviation age ¼ 51.7  11.1, female ratio ¼ 0.41]) comprised DNA
samples from healthy volunteers collected at the Midosuji and other
related rotary clubs of Japan (n ¼ 622) and Tsukuba University
(n ¼ 1,004). PsV was diagnosed in patients via clinical and histo-
pathological findings. The genomic DNA was prepared in accor-
dance with standard protocols. We enrolled 908 healthy controls
used in our previous study for the construction of the HLA imputa-
tion reference panel (Okada et al., 2015). A part of these 908
subjects were also included in the controls of the replication study,
but not included in the GWAS subjects. All subjects were of
Japanese origin and provided written informed consent that was
approved by the ethical committee of each institute.
Statistical power calculation
We estimated statistical power of our study to achieve the
genome-wide significance threshold (a ¼ 5.0  10e8), using aJournal of Investigative Dermatology (2018), Volume 138power.prop.test function implemented in R statistical software
(version 3.1.2). Numbers of the subjects used for power estimates
were harmonic means of the cases and controls in the GWAS or the
meta-analysis of the GWAS and the replication study. The GWAS
and the meta-analysis had power of 6.1% and 80.5% for the MAF in
the controls ¼ 0.20 and OR of the risk variant ¼ 2.5, respectively
(Supplementary Figure S3 online).
Genotyping and quality control in the GWAS
In the GWAS, the PsV cases and controls were genotyped using
illumina HumanCoreExome BeadChip (v1.1; Illumina). We applied
stringent QC filters as described elsewhere (Okada et al., 2014c).
First, we applied QC filters to the subjects: (i) exclusion of samples
with low call rates (<0.99), (ii) exclusion of outliers from the clusters
of East Asian populations in principal component analysis that was
conducted together with HapMap Phase II populations, (iii) exclu-
sion of closely related subjects (identity by descent >0.15). Second,
we applied QC filters to the SNPs: exclusion of SNPs with low call
rates (<0.99), with low MAF (<0.5% in cases or controls), with
Hardy Weinberg equilibrium P-value < 1.0  10e7, or with more
than 0.1 of frequency differences when compared with those in the
1000 Genomes Project (1KG) phase 3v5a Japanese (JPT) subjects.
We also excluded indels or SNPs with duplicated positions. After
applying the QC filters, we estimated principal components using
linkage disequilibrium pruned whole-genome SNP genotype data,
which were then used as covariates in the association analysis.
Genotyping imputation and association analysis in the
GWAS
We conducted whole-genome genotype imputation of the geno-
typed GWAS SNPs. We used a multiethnic reference panel of the
1KG phase 3v5a subjects (n ¼ 2,504). Prephasing of the GWAS data
was performed using SHAPEIT2, and imputation was conducted
using minimac2. We applied postimputation QC filters of MAF
 0.5% in cases and controls, and an imputation score of Rsq  0.7.
Associations of the SNPs with PsV were assessed using logistic
regression analysis with mach2dat. The top two principal compo-
nents were included as covariates.
Replication study
To gain statistical power to finally satisfy the genome-wide signifi-
cance threshold in the meta-analysis of the GWAS and the replica-
tion study, we adopted P < 5.0  10e4 as a threshold for SNP
selection in the replication study. From the loci that satisfied P <
5.0  104 in the GWAS, we selected lead SNPs for the replication
study. SNP genotyping was conducted using the multiplex PCR-
based Invader assay (Hologic, Marlborough, MA). Association
analysis in the replication study was assessed using logistic regres-
sion implemented in R statistical software (version 3.1.2). Meta-
analyses of the GWAS and the replication study were conducted
using a fixed-effect inverse-variance method.
HLA imputation of the GWAS data
Regarding the HLA imputation method, we adopted the HLA refer-
ence panel of the Japanese population that was used in previous
studies (n ¼ 908) (Okada et al., 2015, 2016b; Shiraishi et al., 2016).
In addition to the HLA genes originally incorporated in the reference
panel (HLA-A, HLA-B, and HLA-C for class I; HLA-DRB1, HLA-
DQB1, HLA-DPA1, and HLA-DPB1 for class II), we newly geno-
typed two-digit and four-digit alleles of HLA-DQA1 and integrated
them into the panel to expand coverage of the HLA variants for
imputation. Genotyping of the HLA-DQA1 was performed by a
J Hirata et al.
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with minor modifications. Briefly, exon 1 and exons 2e5 of the HLA-
DQA1 were amplified separately, and then directly sequenced.
Haplotype phasing was performed using Beagle (version 3.3.2), and
deduced haplotypes were used to assign HLA-DQA1 alleles by
comparing with HLA-DQA1 allelic sequences in the Immuno
Polymorphism Database (Robinson et al., 2016). Imputation accu-
racy of the updated reference panel was empirically evaluated by a
cross-validation approach. We randomly split the panel into two
datasets. HLA variants from one of the datasets were masked, and
then imputed using another dataset as a reference. Concordances
between imputed and genotyped HLA variants were calculated. A
leave-one-out cross-validation of HLA-C*06:02 was conducted in
the following steps. (i) For each of the subjects in the reference panel
who had HLA-C*0602, we removed the subject from the reference
panel. (ii) For each, we reconstructed the reference panel using the
rest of the subjects and imputed the HLA alleles of the removed
subject. (iii) We checked whether HLA-C*06:02 was correctly
imputed.
On the basis of the updated reference panel, we applied HLA
imputation using SNP2HLA (Jia et al., 2013; Okada et al., 2014b;
Raychaudhuri et al., 2012). We extracted the SNPs located in the
MHC region (defined as from 29 to 34 Mbp at chromosome 6, NCBI
build 37) from the GWAS data, and imputed genotypes of the alleles
and amino acid polymorphisms of the HLA genes, as well as of the
additional SNPs in the reference panel. We applied a postimputation
QC filter of MAF  0.1% for the HLA variants and MAF  0.5% for
the SNPs with an imputation score of Rsq  0.5.
Fine-mapping analysis of the HLA variants
Associations of the HLA variants with PsV risk were evaluated using
logistic regression implemented in R statistical software (version
3.1.2). We assumed additive effects of the allele dosages on the log-
odds scale. We defined the HLA variants as biallelic SNPs in the
MHC region, two-digit and four-digit biallelic HLA alleles, biallelic
HLA amino acid polymorphisms corresponding to their respective
residues, and multiallelic HLA amino acid polymorphisms for each
amino acid position. To robustly account for potential population
stratification, we included the top five principal components as
covariates.
An omnibus P-value for each HLA amino acid site was calculated
by a log-likelihood ratio test comparing the likelihood of the null
model against the fitted model. The significance of the improvement
in model fitting was evaluated by calculating the deviance, which
follows a c2 distribution with m  1 degree(s) of freedom for an
amino acid position with m residues. A significance threshold was
set according to Bonferroni’s correction based on the number of the
tested variants within the MHC region (a ¼ 0.05).
Conditional association analysis of the HLA variant(s) was
conducted by additionally including the HLA variant genotypes as
covariates. When conditioning on the HLA genes, we included all
the two-digit and four-digit alleles as covariates. We applied a for-
ward stepwise conditional analysis based on the regional signifi-
cance threshold. Using the HLA variants selected from the
conditional analysis results, we performed a multivariate regression
analysis. A proportion of the overall PsV risk in the population (i.e.,
phenotypic variance) explained by the risk of HLA variants was
estimated based on a liability threshold model under the assumption
of a disease prevalence of 0.2% (Kubota et al., 2015; Naito et al.,
2016; Takahashi et al., 2009). Nonadditive effects of the HLAvariants were evaluated by additionally including nonadditive
genotype dosages of the HLA variants as covariates.
Data availability
The PsV case-control GWAS data are deposited at National
BioScience Database Center with the accession ID: hum0114.v1
(https://humandbs.biosciencedbc.jp/hum0114-v1). The updated
HLA imputation reference panel is deposited at National BioScience
Database Center with the accession ID: hum0028.v1 (https://
humandbs.biosciencedbc.jp/hum0028-v1).
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